Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaat4921. doi: 10.1126/scitranslmed.aat4921.

PMID:
30404863
2.

Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer.

Fransen van de Putte EE, Pos F, Doodeman B, van Rhijn BWG, van der Laan E, Nederlof P, van der Heijden MS, van der Hulst JB, Sanders J, Broeks A, Kerst JM, van der Noort V, Horenblas S, Bergman AM.

J Urol. 2018 Oct 12. pii: S0022-5347(18)43985-7. doi: 10.1016/j.juro.2018.10.007. [Epub ahead of print]

PMID:
30321552
3.

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS.

Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30685-7. doi: 10.1016/j.eururo.2018.09.022. [Epub ahead of print] Review.

PMID:
30274701
4.

Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, Van Kessel KE, Voskuilen CS, Winters B, Erho NG, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.1106.2018. doi: 10.1158/1078-0432.CCR-18-1106. [Epub ahead of print]

PMID:
30224344
5.

Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.

Hermans TJN, Voskuilen CS, Deelen M, Mertens LS, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, Pos FJ, de Wit R, Beerepoot LV, Verhoeven RHA, van Rhijn BWG.

Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31833. [Epub ahead of print]

PMID:
30155893
6.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

PMID:
29672836
7.

Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.

Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seiler R, Black PC, Boormans JL, Dall Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BWG, van der Heijden MS, Hsieh AC, Wright JL, Lam HM.

Urol Oncol. 2018 Jul;36(7):342.e7-342.e14. doi: 10.1016/j.urolonc.2018.03.016. Epub 2018 Apr 12.

8.

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T.

Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14.

9.

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I, Théodore C, Grande E, Shen X, Wang J, Nelson B, Derleth CL, van der Heijden MS.

Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31015-1. doi: 10.1016/j.eururo.2017.11.023. [Epub ahead of print]

PMID:
29273410
10.

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A.

Lancet. 2018 Feb 24;391(10122):748-757. doi: 10.1016/S0140-6736(17)33297-X. Epub 2017 Dec 18. Erratum in: Lancet. 2018 Oct 20;392(10156):1402.

PMID:
29268948
11.

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.

Hermans TJN, Voskuilen CS, van der Heijden MS, Schmitz-Dräger BJ, Kassouf W, Seiler R, Kamat AM, Grivas P, Kiltie AE, Black PC, van Rhijn BWG.

Urol Oncol. 2018 Sep;36(9):413-422. doi: 10.1016/j.urolonc.2017.10.014. Epub 2017 Nov 8. Review.

PMID:
29128420
12.

Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.

Szabados B, van Dijk N, Tang YZ, van der Heijden MS, Wimalasingham A, Gomez de Liano A, Chowdhury S, Hughes S, Rudman S, Linch M, Powles T.

Eur Urol. 2018 Feb;73(2):149-152. doi: 10.1016/j.eururo.2017.08.022. Epub 2017 Sep 13.

PMID:
28917596
13.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators.

Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12.

PMID:
28916371
14.

Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.

Patel KM, van der Vos KE, Smith CG, Mouliere F, Tsui D, Morris J, Chandrananda D, Marass F, van den Broek D, Neal DE, Gnanapragasam VJ, Forshew T, van Rhijn BW, Massie CE, Rosenfeld N, van der Heijden MS.

Sci Rep. 2017 Jul 17;7(1):5554. doi: 10.1038/s41598-017-05623-3.

15.

FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.

van de Putte EEF, Vegt E, Mertens LS, Bruining A, Hendricksen K, van der Heijden MS, Horenblas S, van Rhijn BWG.

Int Urol Nephrol. 2017 Sep;49(9):1585-1591. doi: 10.1007/s11255-017-1637-4. Epub 2017 Jul 3.

PMID:
28674853
16.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
17.

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

Wang L, Šuštić T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den Heuvel MM, Bernards R, van der Heijden MS.

Eur Urol. 2017 Jun;71(6):858-862. doi: 10.1016/j.eururo.2017.01.021. Epub 2017 Jan 17.

PMID:
28108151
18.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group.

Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum in: Lancet. 2017 Aug 26;390(10097):848.

19.

Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.

Hermans TJ, Fransen van de Putte EE, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, de Wit R, Beerepoot LV, Verhoeven RH, van Rhijn BW.

Eur J Cancer. 2016 Dec;69:1-8. doi: 10.1016/j.ejca.2016.09.015. Epub 2016 Oct 27.

PMID:
27814469
20.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans EM, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R.

Clin Cancer Res. 2016 Nov 1;22(21):5238-5248. Epub 2016 May 12.

21.

Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer.

van Kessel KE, de Haan LM, Fransen van de Putte EE, van Rhijn BW, de Wit R, van der Heijden MS, Zwarthoff EC, Boormans JL.

Bladder Cancer. 2016 Jul 27;2(3):351-360.

22.

Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.

Chedgy EC, Douglas J, Wright JL, Seiler R, van Rhijn BW, Boormans J, Todenhöfer T, Dinney CP, Collins CC, Van der Heijden MS, Black PC.

Urol Oncol. 2016 Oct;34(10):469-76. doi: 10.1016/j.urolonc.2016.05.012. Epub 2016 Jun 15. Review.

PMID:
27317490
23.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

24.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R.

Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.

25.

Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands.

Hermans TJN, Fransen van de Putte EE, Horenblas S, Lemmens V, Aben K, van der Heijden MS, Beerepoot LV, Verhoeven RH, van Rhijn BWG.

Eur J Cancer. 2016 Feb;54:18-26. doi: 10.1016/j.ejca.2015.11.006. Epub 2015 Dec 18.

PMID:
26707593
26.

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.

van de Putte EE, Mertens LS, Meijer RP, van der Heijden MS, Bex A, van der Poel HG, Kerst JM, Bergman AM, Horenblas S, van Rhijn BW.

World J Urol. 2016 Feb;34(2):157-62. doi: 10.1007/s00345-015-1636-y. Epub 2015 Jul 17.

PMID:
26184106
28.

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.

Groenendijk FH, de Jong J, Fransen van de Putte EE, Michaut M, Schlicker A, Peters D, Velds A, Nieuwland M, van den Heuvel MM, Kerkhoven RM, Wessels LF, Broeks A, van Rhijn BW, Bernards R, van der Heijden MS.

Eur Urol. 2016 Mar;69(3):384-8. doi: 10.1016/j.eururo.2015.01.014. Epub 2015 Jan 27.

PMID:
25636205
29.

The molecular background of urothelial cancer: ready for action?

van der Heijden MS, van Rhijn BW.

Eur Urol. 2015 Feb;67(2):202-3. doi: 10.1016/j.eururo.2014.07.017. Epub 2014 Aug 4. No abstract available.

PMID:
25103696
30.

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.

Wolf SE, Meenken C, Moll AC, Haanen JB, van der Heijden MS.

BMC Cancer. 2013 Dec 1;13:561. doi: 10.1186/1471-2407-13-561.

31.

Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.

Mertens LS, Meijer RP, Meinhardt W, van der Poel HG, Bex A, Kerst JM, van der Heijden MS, Bergman AM, Horenblas S, van Rhijn BW.

BJU Int. 2014 Jul;114(1):67-74. doi: 10.1111/bju.12447. Epub 2014 Jan 17.

32.

Inhibition of the PI3K pathway: hope we can believe in?

van der Heijden MS, Bernards R.

Clin Cancer Res. 2010 Jun 15;16(12):3094-9. doi: 10.1158/1078-0432.CCR-09-3004. Epub 2010 Apr 16.

33.

Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.

Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeier E, Zhu H, van der Heijden MS, Winter JM, Wikiewicz AK, Yeo CJ, Kern SE.

Cancer Res. 2009 Feb 1;69(3):984-91. doi: 10.1158/0008-5472.CAN-08-3610. Epub 2009 Jan 20.

35.

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE.

Clin Cancer Res. 2005 Oct 15;11(20):7508-15.

36.

Functional defects in the fanconi anemia pathway in pancreatic cancer cells.

van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE.

Am J Pathol. 2004 Aug;165(2):651-7.

37.

Mutational analysis of the tyrosine phosphatome in colorectal cancers.

Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE.

Science. 2004 May 21;304(5674):1164-6.

38.

Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot.

Van Der Heijden MS, Brody JR, Kern SE.

Cancer Biol Ther. 2004 Jun;3(6):534-7. Epub 2004 Jun 18.

PMID:
15107617
39.

Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss.

Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, Troup WJ, Romm JM, Doheny K, Pugh E, Yeo CJ, Goggins MG, Hruban RH, Kern SE.

Cancer Res. 2004 Feb 1;64(3):871-5.

40.

The genetics of FANCC and FANCG in familial pancreatic cancer.

Rogers CD, van der Heijden MS, Brune K, Yeo CJ, Hruban RH, Kern SE, Goggins M.

Cancer Biol Ther. 2004 Feb;3(2):167-9. Epub 2004 Feb 1.

PMID:
14726700
41.

Trans-cellular proliferating cell nuclear antigen gene activation in cerebral vascular smooth muscle by endothelial oxidative injury in vivo.

Gerzanich V, Ivanova S, van der Heijden MS, Zhou H, Simard JM.

Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2048-54. Epub 2003 Sep 11.

PMID:
12969989
42.

Fanconi anemia gene mutations in young-onset pancreatic cancer.

van der Heijden MS, Yeo CJ, Hruban RH, Kern SE.

Cancer Res. 2003 May 15;63(10):2585-8.

43.

Fatty acid composition of plasma lipids in patients with pancreatic, lung and oesophageal cancer in comparison with healthy subjects.

Zuijdgeest-van Leeuwen SD, van der Heijden MS, Rietveld T, van den Berg JW, Tilanus HW, Burgers JA, Wilson JH, Dagnelie PC.

Clin Nutr. 2002 Jun;21(3):225-30.

PMID:
12127931

Supplemental Content

Loading ...
Support Center